Opendata, web and dolomites

PREMEDiCARE SIGNED

PREcision MEDicine with induced pluripotent stem cells for Cardiac Arrhythmias Risk Evaluation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PREMEDiCARE project word cloud

Explore the words cloud of the PREMEDiCARE project. It provides you a very rough idea of what is the project "PREMEDiCARE" about.

advancements    pathogenic    severity    patient    safe    qt    clinical    symptomatic    pluripotent    treatments    matched    syndromes    male    humans    disease    vs    arrhythmias    poorly    therapy    personalised    risk    genotype    medicine    vulnerable    cells    mutation    identical    death    phenotype    physiological    human    prolongation    first    animal    hpsc    molecular    phenotypes    asymptomatic    carriers    applicable    create    uses    rare    protect    reduce    contractile    severe    safer    acquired    revealed    lqts    population    models    cardiomyocytes    stem    preclinical    genetic    long    vitro    reproduce    stratification    electrocardiogram    predisposed    families    hipsc    electrophysiological    unpredictable    patients    mutations    links    susceptibility    proarrhythmic    interval    characterised    female    caused    simulate    arrhythmia    pipeline    cardiac    shift    interdisciplinary    drugs    assays    syndrome    subjects    diagnosis    shape    drug    therapeutic    congenital    arrhythmogenic    sudden    combines    cms    manifestations    screenings    precision    profound    pharmacological   

Project "PREMEDiCARE" data sheet

The following table provides information about the project.

Coordinator
ISTITUTO AUXOLOGICO ITALIANO 

Organization address
address: VIA L. ARIOSTO 13
city: MILANO
postcode: 20145
website: www.auxologico.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 168˙277 €
 EC max contribution 168˙277 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ISTITUTO AUXOLOGICO ITALIANO IT (MILANO) coordinator 168˙277.00

Map

 Project objective

Long QT Syndrome (LQTS) is a severe arrhythmogenic condition characterised by the prolongation of the QT interval on the electrocardiogram. It is caused by genetic factors (congenital) or drugs (acquired) and sudden cardiac death can be the first manifestations of the disease. Advancements in genetic screenings have revealed profound links between genotype and phenotype for LQTS, improving diagnosis, risk stratification and therapy; However, it is still poorly understood why patients with identical pathogenic mutations have different clinical phenotypes, which factors are involved in this unpredictable disease severity and how we can protect these subjects from drug treatments that are safe in the general population. We do need improved and more physiological in vitro models to simulate arrhythmias in vitro, effective for drug testing, to identify, evaluate and study factors that shape the arrhythmogenic risk in vulnerable subjects. Here I propose a precision medicine approach that uses human pluripotent stem cells-derived cardiomyocytes (hPSC-CMs) from LQTS families (rare resources that include male, female, symptomatic and asymptomatic patients) to: i) demonstrate that the hiPSC technology can reproduce in vitro the clinical disease severity observed in symptomatic vs asymptomatic LQTS mutation carriers; ii) create an in vitro interdisciplinary pharmacological approach with proarrhythmic drugs which combines matched electrophysiological, contractile, molecular and genetic assays; iii) identify and evaluate the factors affecting the arrhythmogenic risk in predisposed subjects. This pipeline to assess arrhythmia susceptibility from patient-specific hiPSC-CMs can be applicable to other arrhythmogenic syndromes. The results of this project will contribute to reduce the use of animal models in preclinical research, to create safer, more effective drugs for humans and to promote the shift of new therapeutic approaches towards precision or personalised medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREMEDICARE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREMEDICARE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MultiSeaSpace (2019)

Developing a unified spatial modelling strategy that accounts for interactions between species at different marine trophic levels, and different types of survey data.

Read More  

LIGHTMATT-EXPLORER (2019)

Experimental determination of the paraxial-vectorial limit of light-matter interactions

Read More  

Goc-MM (2019)

Human gut microbiota on gut-on-a-chip

Read More